长春西汀联合丁苯酞、瑞舒伐他汀治疗对急性脑梗死患者脑血管储备能力及血清CRP、MMP-9的影响  

Effect of vinpocetine combined with butylphthalide and rosuvastatin on cerebral vascular reserve and serum CRP and MMP-9 in patients with acute cerebral infarction

作　　者：吴镇 Wu Zhen(Department 1 of Dexing Traditional Chinese Medicine Hospital,Shangrao,Jiangxi 334200,China)

机构地区：[1]德兴中医院内一科,江西上饶334200

出　　处：《四川生理科学杂志》2024年第6期1303-1305,1342,共4页Sichuan Journal of Physiological Sciences

摘　　要：目的:观察长春西汀联合丁苯酞、瑞舒伐他汀治疗急性脑梗死(Acute cerebral infarct,ACI)患者对其脑血管储备能力及血清中C反应蛋白(C-reactive protein,CRP)、基质金属蛋白酶-9(Matrix metalloproteinase-9,MMP-9)水平的影响。方法:选取2022年8月至2023年5月间在我院接受治疗的80例ACI患者,随机分成二联组和三联组(n=40)。二联组患者每日静注丁苯酞100 mL+口服瑞舒伐他汀20 mL治疗,三联组在此基础上加静注长春西汀20 mL治疗,疗程均为2 w。治疗前、后采用经颅超声多普勒(Transcranial Doppler,TCD)屏气试验检查脑血管储备能力(Cerebrovascular reserve,CVR),包括动脉血流速度(Mean flow velocity,MFV)、屏气指数(Breath-holding index,BHI)、搏动指数(Pulsitility index,PI);用生化分析仪测量血清CRP水平;以酶联免疫吸附法检测血清MMP-9水平;同时比较症状改善状况及不良发应发生率。结果:三联组患者CVR、MFV、BHI水平明显高于二联组,三联组PI水平,显著低于二联组(P<0.05);三联组血清CRP、MMP-9水平均低于二联组(P<0.05);三联组总有效率显著高于二联组(P<0.05);三联组不良反应发生率与二联组相当(P>0.05)。结论:长春西汀联合丁苯酞、瑞舒伐他汀对可显著提高ACI患者的CVR,降低炎症因子CRP、MMP-9的水平,疗效显著,安全性好。Objective:To observe the effects of vinpocetine combined with butylphthalide and rosuvastatin on the cerebrovascular reserve capacity and serum levels of C-reactive protein(CRP)and matrix metalloproteinase-9(MMP-9)in patients with acute cerebral infarction(ACI).Method:Eighty patients with ACI who received treatment in our hospital from August 2022 to May 2023 were randomly divided into a dual-drug group and a triple-drug group(n=40).The dual-drug group received intravenous administration of 100 mL of butylphthalide and oral administration of 20 mL of rosuvastatin daily,while the triple-drug group received intravenous administration of 20 mL of vinpocetine in addition to the above treatments.Both groups underwent a treatment course of 2 weeks.Before and after treatment,transcranial Doppler(TCD)breath-holding test was used to examine cerebrovascular reserve capacity(CVR),including arterial flow velocity(MFV),breath-holding index(BHI),and pulsatility index(PI).Serum CRP levels were measured using a biochemical analyzer,and serum MMP-9 levels were detected using enzyme-linked immunosorbent assay.At the same time,the improvement of symptoms and the incidence of adverse reactions were compared.Results:The levels of CVR,MFV,and BHI in the triple-drug group were significantly higher than those in the dual-drug group,while the level of PI in the triple-drug group was significantly lower than that in the dual-drug group(P<0.05).The levels of serum CRP and MMP-9 in the triple-drug group were lower than those in the dual-drug group(P<0.05).The total effective rate in the triple-drug group was significantly higher than that in the dual-drug group(P<0.05).The incidence of adverse reactions in the triple-drug group was comparable to that in the dual-drug group(P>0.05).Conclusion:Vinpocetine combined with butylphthalide and rosuvastatin can significantly improve CVR in patients with ACI,reduce the levels of inflammatory factors CRP and MMP-9,and have significant efficacy and good safety.

关 键 词：长春西汀 丁苯酞 瑞舒伐他汀 急性脑梗死 C反应蛋白 基质金属蛋白酶-9 

分 类 号：R743.33[医药卫生—神经病学与精神病学]